Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 12/20 | 0.46 |
| ▸ | FNTB | P49356 | 12/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.43 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373210 | 0.91 | MAPT (0.45) | FNTAFNTBGABBR2GABBR1ALDH1A1 | |
| SCHEMBL12617086 | 0.85 | FNTA (0.45) | FNTAFNTBALDH1A1HPGDCASR | |
| SCHEMBL16221618 | 0.81 | TDP1 (0.47) | FNTAFNTBGABBR2GABBR1 | |
| SCHEMBL12373215 | 0.77 | MAPT (0.43) | FNTAFNTBALDH1A1HPGD | |
| SCHEMBL1998497 | 0.76 | FNTA (0.54) | FNTAFNTBGABBR2GABBR1ALDH1A1 | |
| SCHEMBL24579667 | 0.75 | KMT2A (0.64) | ALDH1A1 | |
| SCHEMBL2001935 | 0.73 | FNTA (0.50) | FNTAFNTBALDH1A1 | |
| SCHEMBL2001988 | 0.73 | RAB9A (0.57) | FNTAFNTBALDH1A1CASR | |
| SCHEMBL29775255 | 0.71 | LOXL2 (0.51) | ALDH1A1HPGD | |
| SCHEMBL24579101 | 0.71 | LOXL2 (0.51) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201576-A1 | Small molecule inhibitors of stat3 with anti-tumor activity | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-7960434-B2 | Small molecule inhibitors of STAT3 with anti-tumor activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090069420-A1 | Small molecule inhibitors of STAT3 with anti-tumor activity | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201576-A1 | Small molecule inhibitors of stat3 with anti-tumor activity | STAT3, STAT1, STAT5A | FNTA 2310/4885FNTB 1660/4885GABBR2 4571/4885 |
| US-20090069420-A1 | Small molecule inhibitors of STAT3 with anti-tumor activity | STAT3, STAT1, STAT5A | FNTA 2310/4885FNTB 1660/4885GABBR2 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.